Economic Considerations in the Prescribing of Third-Generation Antidepressants

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.23, Iss.5, 2005-01, pp. : 477-491

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Third-Generation Antidepressants: Do They Offer Advantages Over the SSRIs?

By Olver J.S. Burrows G.D. Norman T.R.

CNS Drugs, Vol. 15, Iss. 12, 2001-01 ,pp. : 941-954

Adis International

Access to resources Recommend Favorite

Pharmacogenomics of third-generation aromatase inhibitors

By Turkistani Abdullah Marsh Sharon

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 9, 2012-06 ,pp. : 1299-1307

Informa Healthcare

Access to resources Recommend Favorite

Third-generation sequencing techniques and applications to drug discovery

By Ozsolak Fatih

Expert Opinion on Drug Discovery, Vol. 7, Iss. 3, 2012-03 ,pp. : 231-243

Informa Healthcare

Access to resources Recommend Favorite

Increased VTE risk of third-generation OCs not supported

Inpharma, Vol. 1, Iss. 1252, 2000-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Third-generation OCs: increased VTE risk supported by new analyses

Inpharma, Vol. 1, Iss. 1264, 2000-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite